Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

• Status: Suspended
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Panitumumab

Criteria

Inclusion Criteria:

• Confirmed diagnosis of pancreatic cancer.

Exclusion Criteria:

• Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.

• History of infusion reactions to monoclonal antibody therapies.

• Pregnant or breastfeeding.

• Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.

• Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.

• Severe renal disease or anuria.

• Known hypersensitivity to deferoxamine or any of its components.